NCT04748276Recruiting
Tracking Response to Antidepressants in Advance of Investigational Trials
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
TRAIT is an open-label observational study to evaluate treatment response to selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs) among individuals meeting criteria for Major Depressive Disorder (MDD) and seeking enrollment in investigational trials.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 7 Feb 2021
- Start date
- 2 Jan 2019
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Adams Clinical
- Diseases
- Depression
- NCT number
- NCT04748276
What you commit to
- Study type: Observational
- Planned participants: 400
- From 2 Jan 2019 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the opinion of the investigator could pose undue risk to the participant, or compromise the study.
Other illness
- Participant has a history of any psychiatric condition other than MDD, which in the opinion of the investigator is primary, or any other psychiatric or neurologic disorder or symptom that could pose undue risk to the participant or compromise the study.
- Any condition that, in the opinion of the investigator, makes the participant unsuitable for the study.
Other
- Participant is pregnant, breast-feeding, or planning to become pregnant.
- A history or presence of a clinically significant hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, or neurologic abnormality, which in the opinion of the investigator may impact participant safety or study results.
- Any participant who represents an acute suicidal risk in the opinion of the investigator.
Who the study is looking for
- Participant has signed an ICF prior to any study-specific procedures being performed.
- Participant is male or female of age ≥ 18 years old.
- Participant has a diagnosis of MDD as confirmed by the MINI semi-structured diagnostic interview and ≥ 14 HAM-D total score.
- Participant is in good physical health and, in the opinion of the investigator, is a suitable candidate for treatment with an ADT.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Adams Clinical Coordinator of this site? Confirm its status | Watertown | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.